http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-200714605-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
filingDate 2006-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21f736c394e6f078a9fc4f87c318360f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5784d748f1281ae814896cff35f6b52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46b77e694da7e28264f8f7d48f286f64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cd83c292392462041c40b43d7444e08
publicationDate 2007-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber TW-200714605-A
titleOfInvention Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
abstract There are disclosed novel 5-substituted 7-amino-[l,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I), wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.
priorityDate 2005-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP49238
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10351759
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA6QNL7
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13051
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID171056
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100124525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414781926
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35411
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1524
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9Z0D9

Total number of triples: 39.